Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It provides long‑term contraception by preventing fertilization and implantation in women of reproductive age. The device releases levonorgestrel continuously for up to five years, offering a reversible, hormone‑based birth control option.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution, ensuring compliance with international pharmacopeial specifications.

Kyleena, a hormonal contraceptive delivered via an intrauterine system, is indicated for prevention of pregnancy. - Contraception: up to five years of effective pregnancy prevention. - Reversible birth control: fertility typically returns promptly after device removal. - Hormonal contraception: provides continuous low‑dose levonorgestrel release within the uterine cavity.

Levonorgestrel IUS may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Irregular bleeding: changes in menstrual pattern, including spotting or prolonged bleeding. - Spotting between periods: light bleeding outside scheduled menses. - Headache: mild to moderate intensity. - Breast tenderness: discomfort or soreness of the breasts.

Serious or Rare Side Effects: - Pelvic inflammatory disease: infection of the reproductive organs that may require treatment. - Uterine perforation: rare injury to the uterine wall during insertion. - Ectopic pregnancy: pregnancy occurring outside the uterus if contraceptive failure occurs.

Before initiating Kyleena therapy, healthcare providers should consider several precautionary measures to ensure patient safety. - Screen for uterine abnormalities: confirm absence of fibroids, polyps, or congenital anomalies that could impede device placement. - Avoid if active pelvic infection: insertion may exacerbate infection and increase risk of complications. - Check for hormonal contraindications: assess history of thromboembolic disorders, liver disease, or hormone‑sensitive cancers. - Consider breastfeeding status: discuss potential effects with lactating patients and evaluate suitability. - Store at room temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from an intrauterine system can interact with other medications, influencing its contraceptive effectiveness.

Major Interactions (Avoid): - Antiepileptic enzyme inducers: drugs such as carbamazepine or phenytoin may reduce levonorgestrel levels and compromise efficacy. - Rifampin and other strong rifamycin antibiotics: can markedly decrease hormone concentrations, increasing risk of unintended pregnancy.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase levonorgestrel exposure, requiring monitoring for hormonal side effects. - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly lower hormone effectiveness; advise backup contraception if needed. - Herbal supplements such as St. John’s wort: can induce hepatic enzymes and potentially reduce contraceptive reliability.